,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'tnbc', 'breast', 'destiny-breast04']
findings yesterday at #asco22 likely create new treatment target for people with her2-low (ihc 1+ and 2+) hr+ #metastaticbreastcancer, and possibly for those with mtnbc as well. learn more about the landmark destiny-breast04 trial in our asco coverage: 
The mission of Living Beyond Breast Cancer (LBBC) is to connect people with trusted breast cancer information and a community of support.